Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.

Mario CamponeMichelino De LaurentiisClaudio ZamagniIgor KudryavcevMariëtte AgterofUrsa Brown-GlabermanMarkéta PalácováSanjoy ChatterjeeLakshmi Menon-SinghJiwen WuMiguel Martín

Published in: Breast cancer research and treatment (2022)

NCT02941926 (Registered 2016).

Keyphrases

epidermal growth factor receptor
tyrosine kinase
advanced non small cell lung cancer
phase iii
endothelial cells
clinical trial
induced pluripotent stem cells
phase ii
polycystic ovary syndrome
pluripotent stem cells
open label
type diabetes
metabolic syndrome
insulin resistance
young adults
childhood cancer